ArticleNature cancer2024
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.
Abstract read
In one paragraph
Article in Nature cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients.Clinical pharmacology and therapeutics · 2026Trial
- Review
- Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma.HemaSphere · 2026Article
- Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.Clinical pharmacology and therapeutics · 2026Article
- From Prediction to Decision Making: PBPK and QSP as Regulatory-Grade NAMs.Clinical pharmacology and therapeutics · 2026Review
- TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy.Science advances · 2026Article
- T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.Signal transduction and targeted therapy · 2026Review
- Quantitative Systems Pharmacology (QSP): Bridging Biology and Mechanism with Clinical Drug Development Decisions.Journal of clinical pharmacology · 2026Review
- Model-Informed Decision Making from Drug Discovery to Reimbursement: A Roadmap for Clinical Pharmacology in Value-Based Healthcare.Journal of clinical pharmacology · 2026Review
- Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma.Cancer · 2026Article
- A simple algebraic expression can determine if a drug's clearance is non-specific or target-mediated.Journal of pharmacokinetics and pharmacodynamics · 2026Article
- Navigating the Therapeutic Landscape of Multiple Myeloma: Immunotherapy, Microenvironment, and Resistance.Biomedicines · 2026Review
- Elranatamab: Mechanism of Action, Clinical, and Translational Science.Clinical and translational science · 2026Review
- Oncolytic adenoviruses encoding bispecific T cell engagers or a novel trispecific T cell engager for dual-targeting of c-MET and EGFR.Molecular therapy. Oncology · 2026Article
- Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors.Frontiers in immunology · 2026Review
- Emerging precision medicine in multiple myeloma: clinical and preclinical landscape of T cell, natural killer cell, and macrophages engaging multi-specific antibodies.Frontiers in immunology · 2026Review
- Next-generation T cell engagers for cancer and autoimmune diseases.Frontiers in immunology · 2026Review
- Advancing immunotherapy via multiple immune cells co-engagement.Frontiers in immunology · 2026Review
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Laura Carretero-IglesiaIchnos Glenmark Innovation, New York, NY, USA.
Olivia J HallIchnos Glenmark Innovation, New York, NY, USA.
Jérémy BerretIchnos Glenmark Innovation, New York, NY, USA.
Daniela PaisIchnos Glenmark Innovation, New York, NY, USA.
Carole EstoppeyIchnos Glenmark Innovation, New York, NY, USA.
Myriam ChimenIchnos Glenmark Innovation, New York, NY, USA.
Thierry MonneyIchnos Glenmark Innovation, New York, NY, USA.ORCID 0000-0002-8566-541X
Jeremy LoyauIchnos Glenmark Innovation, New York, NY, USA.
Cyrille DreyfusIchnos Glenmark Innovation, New York, NY, USA.
Julie MacoinIchnos Glenmark Innovation, New York, NY, USA.
Cynthia PerezIchnos Glenmark Innovation, New York, NY, USA.
Vinu MenonIchnos Glenmark Innovation, New York, NY, USA.
Isabelle GruberIchnos Glenmark Innovation, New York, NY, USA.
Amélie LaurendonIchnos Glenmark Innovation, New York, NY, USA.
Lydia N CaroIchnos Glenmark Innovation, New York, NY, USA.
Girish S GudiIchnos Glenmark Innovation, New York, NY, USA.
Tomomi MatsuuraCertara UK Limited, Canterbury Innovation Centre, University Road, Canterbury, United Kingdom.
Piet H van der GraafCertara UK Limited, Canterbury Innovation Centre, University Road, Canterbury, United Kingdom.
Stanislas BleinIchnos Glenmark Innovation, New York, NY, USA.
M Lamine MbowIchnos Glenmark Innovation, New York, NY, USA.
Rebecca Croasdale-WoodIchnos Glenmark Innovation, New York, NY, USA.
Ankita SrivastavaIchnos Glenmark Innovation, New York, NY, USA.
Michael R DysonIchnos Glenmark Innovation, New York, NY, USA.ORCID 0000-0002-8382-0789
Thomas MatthesHematology Service, Department of Oncology and Clinical Pathology Service, Department of Diagnostics, University Hospital Geneva, Geneva, Switzerland.ORCID 0000-0002-4875-2477
Zeynep KayaNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute, University of Oxford, Oxford, United Kingdom.
Claire M EdwardsNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-1257-5659
James R EdwardsNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-7391-0820
Sophie MaigaNantes Université, Inserm, CNRS, Université d'Angers, Nantes, France.
Catherine Pellat-DeceunynckNantes Université, Inserm, CNRS, Université d'Angers, Nantes, France.ORCID 0000-0002-6287-8148
Cyrille TouzeauNantes Université, Inserm, CNRS, Université d'Angers, Nantes, France.
Philippe MoreauNantes Université, Inserm, CNRS, Université d'Angers, Nantes, France.
Cyril KontoIchnos Glenmark Innovation, New York, NY, USA.
Adam DrakeIchnos Glenmark Innovation, New York, NY, USA.
Eugene A ZhukovskyIchnos Glenmark Innovation, New York, NY, USA.
Mario Perro *Ichnos Glenmark Innovation, New York, NY, USA. mario.perro@iginnovate.com.ORCID 0000-0003-1375-8155
Maria Pihlgren *Ichnos Glenmark Innovation, New York, NY, USA.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent advances in immunotherapies targeting single tumor-associated antigens, patients with multiple myeloma eventually relapse. ISB 2001 is a CD3
Indexed as
ADP-ribosyl Cyclase 1Multiple MyelomaTumor EscapeAnimalsAntigens, NeoplasmB-Cell Maturation AntigenCell Line, TumorClinical Trials as TopicCytotoxicity, ImmunologicHumansImmunotherapyLymphocyte ActivationMembrane GlycoproteinsMiceT-LymphocytesXenograft Model Antitumor AssaysADP-ribosyl Cyclase 1Antigens, NeoplasmB-Cell Maturation AntigenCD38 protein, humanMembrane Glycoproteins
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.